London
· Delayed Price · Currency is GBP · Price in GBX hVIVO Company Description
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.
The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services.
It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD.
In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development.
Further, it provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services.
The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022.
hVIVO plc is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 301 |
| CEO | Yamin Khan |
Contact Details
Address: 40 Bank Street London, E14 5NR United Kingdom | |
| Phone | 44 20 7756 1300 |
| Website | hvivo.com |
Stock Details
| Ticker Symbol | HVO |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00B9275X97 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Yamin Khan | Chief Executive Officer |
| Stephen Pinkerton | Chief Financial Officer |